The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Mechanisms of neuroblastoma regression
Open accessAbstract
Recent genomic and biological studies of neuroblastoma have shed light on the dramatic heterogeneity in the clinical behaviour of this disease, which spans from spontaneous regression or differentiation in some patients, to relentless disease progression in others, despite intensive multimodality therapy. This evidence also suggests several possible mechanisms to explain the phenomena of spontaneous regression in neuroblastomas, including neurotrophin deprivation, humoral or cellular immunity, loss of telomerase activity and alterations in epigenetic regulation. A better understanding of the mechanisms of spontaneous regression might help to identify optimal therapeutic approaches for patients with these tumours. Currently, the most druggable mechanism is the delayed activation of developmentally programmed cell death regulated by the tropomyosin receptor kinase A pathway. Indeed, targeted therapy aimed at inhibiting neurotrophin receptors might be used in lieu of conventional chemotherapy or radiation in infants with biologically favourable tumours that require treatment. Alternative approaches consist of breaking immune tolerance to tumour antigens or activating neurotrophin receptor pathways to induce neuronal differentiation. These approaches are likely to be most effective against biologically favourable tumours, but they might also provide insights into treatment of biologically unfavourable tumours. We describe the different mechanisms of spontaneous neuroblastoma regression and the consequent therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
The history of cancer epigenetics
Feinberg, A. P., & Tycko, B. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1279 · Cited by 2,344
Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L., Castel, V, Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., & Hedborg, F. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1466 · Cited by 2,294
Self-citationNeuroblastoma: biological insights into a clinical enigma
Brodeur, G. M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1014 · Cited by 2,160
Self-citationMaris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60983-0 · Cited by 2,032
Self-citationPrinciples and Practice of Pediatric Oncology
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-8-636_3 · Cited by 2,027
Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898
Self-citationAnti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Identification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407
Self-citationThe genetic landscape of high-risk neuroblastoma
Pugh, T. J., Morozova, O., Attiyeh, E. F., Asgharzadeh, S., Wei, J. S., Auclair, D., Carter, S. L., Cibulskis, K., Hanna, M., Kiezun, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2529 · Cited by 1,186
Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,163
DNA methylation and gene silencing in cancer
Baylin, S. B. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0354 · Cited by 1,154
The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report
Monclair, T., Brodeur, G. M., Ambros, P. F., Brisse, H. J., Cecchetto, G., Holmes, K., Kaneko, M., London, W. B., Matthay, K. K., Nuchtern, J. G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6876 · Cited by 1,150
Self-citationChildhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study
Gatta, G., Botta, L., Rossi, S., Aareleid, T., Bielska-Lasota, M., Clavel, J., Dimitrova, N., Jakab, Z., Kaatsch, P., Lacour, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70548-5 · Cited by 1,075
The International Neuroblastoma Pathology Classification (the Shimada system)
Shimada, H., Ambros, I. M., Dehner, L. P., Hata, J.-I., Joshi, V. V., Roald, B., Stram, D. O., Gerbing, R. B., Lukens, J. N., Matthay, K. K., et al. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990715)86:2<364::aid-cncr21>3.0.co;2-7 · Cited by 1,067
Principles and Practice of Pediatric Oncology
Labotka, R. J. (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.7.894-a · Cited by 1,046
Outcomes for children and adolescents with cancer: challenges for the twenty-first century
Smith, M. A., Seibel, N. L., Altekruse, S. F., Ries, L. A. G., Melbert, D. L., O'Leary, M., Smith, F. O., & Reaman, G. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0421 · Cited by 1,026
A proposed staging for children with neuroblastoma.Children's cancer study group A
Evans, A. E., D'Angio, G. J., & Randolph, J. (1971) · Cancer · doi:10.1002/1097-0142(197102)27:2<374::aid-cncr2820270221>3.0.co;2-g · Cited by 950
Oncogenic mutations of ALK kinase in neuroblastoma
Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., et al. (2008) · Nature · doi:10.1038/nature07399 · Cited by 916
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Janoueix-Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008) · Nature · doi:10.1038/nature07398 · Cited by 894
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature · doi:10.1038/nature07397 · Cited by 893
Targeted expression of MYCN causes neuroblastoma in transgenic mice
Weiss, W. A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.11.2985 · Cited by 870
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
Molenaar, J. J., Koster, J., Zwijnenburg, D. A., van Sluis, P., Valentijn, L. J., van der Ploeg, I., Hamdi, M., van Nes, J., Westerman, B. A., van Arkel, J., et al. (2012) · Nature · doi:10.1038/nature10910 · Cited by 870
Shimada, H., Chatten, J., Newton, W. A., Sachs, N., Hamoudi, A. B., Chiba, T., Marsden, H. B., & Misugi, K. (1984) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/73.2.405 · Cited by 862
Expression of the c-ret proto-oncogene during mouse embryogenesis
Pachnis, V., Mankoo, B., & Costantini, F. (1993) · Development · doi:10.1242/dev.119.4.1005 · Cited by 837
A BDNF autocrine loop in adult sensory neurons prevents cell death
Acheson, A., Conover, J. C., Fandl, J. P., DeChiara, T. M., Russell, M., Thadani, A., Squinto, S. P., Yancopoulos, G. D., & Lindsay, R. M. (1995) · Nature · doi:10.1038/374450a0 · Cited by 765
Brunia, C. H. M., & van Boxtel, G. J. M. (2001) · International Journal of Psychophysiology · doi:10.1016/s0167-8760(01)00179-9 · Cited by 721
Nakagawara, A., Arima-Nakagawara, M., Scavarda, N. J., Azar, C. G., Cantor, A. B., & Brodeur, G. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199303253281205 · Cited by 694
Self-citationSpontaneous Regression of Cancer
(1966) · The Lancet · doi:10.1016/s0140-6736(66)91989-1 · Cited by 684
Correlating telomerase activity levels with human neuroblastoma outcomes
Hiyama, E., Hiyama, K., Yokoyama, T., Matsuura, Y., Piatyszek, M. A., & Shay, J. W. (1995) · Nature Medicine · doi:10.1038/nm0395-249 · Cited by 611
Brodeur, G. M., Seeger, R. C., Barrett, A., Berthold, F., Castleberry, R. P., D'Angio, G., De Bernardi, B., Evans, A. E., Favrot, M., & Freeman, A. I. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1874 · Cited by 608
Self-citationShimada, H., Ambros, I. M., Dehner, L. P., Hata, J.-I., Joshi, V. V., & Roald, B. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990715)86:2<349::aid-cncr20>3.0.co;2-y · Cited by 586
Shimada, H., Ambros, I. M., Dehner, L. P., Hata, J., Joshi, V. V., & Roald, B. (1999) · PubMed · Cited by 573
Bamji, S. X., Majdan, M., Pozniak, C. D., Belliveau, D. J., Aloyz, R., Kohn, J., Causing, C. G., & Miller, F. D. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.140.4.911 · Cited by 506
Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma
Cheung, N.-K. V. (2012) · JAMA · doi:10.1001/jama.2012.228 · Cited by 468
Neuroblastoma Screening at One Year of Age
Schilling, F. H., Spix, C., Berthold, F., Erttmann, R., Fehse, N., Hero, B., Klein, G., Sander, J., Schwarz, K., Treuner, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012277 · Cited by 464
Expression and function of TRK-B and BDNF in human neuroblastomas.
Nakagawara, A., Azar, C. G., Scavarda, N. J., & Brodeur, G. M. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.759 · Cited by 423
Self-citationSausen, M., Leary, R. J., Jones, S., Wu, J., Reynolds, C. P., Liu, X., Blackford, A., Parmigiani, G., Diaz, L. A., Papadopoulos, N., et al. (2013) · Nature Genetics · doi:10.1038/ng.2493 · Cited by 414
IN SITU NEUROBLASTOMAS: A CONTRIBUTION TO THE NATURAL HISTORY OF NEURAL CREST TUMORS.
Jb, B., & Perrin, E. V. (1963) · PubMed · Cited by 403
SPECIAL PATTERN OF WIDESPREAD NEUROBLASTOMA WITH A FAVOURABLE PROGNOSIS
D'Angio, G., Evans, A., & Koop, C. E. (1971) · The Lancet · doi:10.1016/s0140-6736(71)91606-0 · Cited by 401
Gm, B., Pritchard, J., Berthold, F., Nl, C., Castel, V., Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M., & Hedborg, F. (1994) · PubMed · Cited by 392
LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression
Molenaar, J. J., Domingo-Fernández, R., Ebus, M. E., Lindner, S., Koster, J., Drabek, K., Mestdagh, P., van Sluis, P., Valentijn, L. J., van Nes, J., et al. (2012) · Nature Genetics · doi:10.1038/ng.2436 · Cited by 383
The Spontaneous Regression of Cancer: A review of cases from 1900 to 1987
Challis, G. B., & Stam, H. J. (1990) · Acta Oncologica · doi:10.3109/02841869009090048 · Cited by 372
Germline Mutations of the Paired–Like Homeobox 2B (PHOX2B) Gene in Neuroblastoma
Trochet, D., Bourdeaut, F., Janoueix-Lerosey, I., Deville, A., de Pontual, L., Schleiermacher, G., Coze, C., Philip, N., Frébourg, T., Munnich, A., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/383253 · Cited by 358
Screening of Infants and Mortality Due to Neuroblastoma
Woods, W. G., Gao, R.-N., Shuster, J. J., Robison, L. L., Bernstein, M., Weitzman, S., Bunin, G., Levy, I., Brossard, J., Dougherty, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012387 · Cited by 356
The epigenetics of cancer etiology
Feinberg, A. P. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.06.005 · Cited by 337
The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
Berry, T., Luther, W., Bhatnagar, N., Jamin, Y., Poon, E., Sanda, T., Pei, D., Sharma, B., Vetharoy, W. R., Hallsworth, A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.001 · Cited by 326
Hero, B., Simon, T., Spitz, R., Ernestus, K., Gnekow, A. K., Scheel-Walter, H.-G., Schwabe, D., Schilling, F. H., Benz-Bohm, G., & Berthold, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3349 · Cited by 311
Integrative genomics identifies LMO1 as a neuroblastoma oncogene
Wang, K., Diskin, S. J., Zhang, H., Attiyeh, E. F., Winter, C., Hou, C., Schnepp, R. W., Diamond, M., Bosse, K., Mayes, P. A., et al. (2011) · Nature · doi:10.1038/nature09609 · Cited by 310
Trk Receptor Expression and Inhibition in Neuroblastomas
Brodeur, G. M., Minturn, J. E., Ho, R., Simpson, A. M., Iyer, R., Varela, C. R., Light, J. E., Kolla, V., & Evans, A. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1815 · Cited by 307
Self-citationCommon variations in BARD1 influence susceptibility to high-risk neuroblastoma
Capasso, M., Devoto, M., Hou, C., Asgharzadeh, S., Glessner, J. T., Attiyeh, E. F., Mosse, Y. P., Kim, C., Diskin, S. J., Cole, K. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.374 · Cited by 305
Assembling Neural Crest Regulatory Circuits into a Gene Regulatory Network
Betancur, P., Bronner-Fraser, M., & Sauka-Spengler, T. (2010) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.042308.113245 · Cited by 305
Kreissman, S. G., Seeger, R. C., Matthay, K. K., London, W. B., Sposto, R., Grupp, S. A., Haas-Kogan, D. A., LaQuaglia, M. P., Yu, A. L., Diller, L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70309-7 · Cited by 304
Shimada, H., Umehara, S., Monobe, Y., Hachitanda, Y., Nakagawa, A., Goto, S., Gerbing, R. B., Stram, D. O., Lukens, J. N., & Matthay, K. K. (2001) · Cancer · doi:10.1002/1097-0142(20011101)92:9<2451::aid-cncr1595>3.0.co;2-s · Cited by 294
Hantzopoulos, P. A., Suri, C., Glass, D. J., Goldfarb, M. P., & Yancopoulos, G. D. (1994) · Neuron · doi:10.1016/0896-6273(94)90469-3 · Cited by 288
Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma
Asgharzadeh, S., Salo, J. A., Ji, L., Oberthuer, A., Fischer, M., Berthold, F., Hadjidaniel, M., Liu, C. W.-Y., Metelitsa, L. S., Pique-Regi, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.9169 · Cited by 285
Germline PHOX2B Mutation in Hereditary Neuroblastoma
Mosse, Y. P., Laudenslager, M., Khazi, D., Carlisle, A. J., Winter, C. L., Rappaport, E., & Maris, J. M. (2004) · The American Journal of Human Genetics · doi:10.1086/424530 · Cited by 284
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma
Diskin, S. J., Capasso, M., Schnepp, R. W., Cole, K. A., Attiyeh, E. F., Hou, C., Diamond, M., Carpenter, E. L., Winter, C., Lee, H., et al. (2012) · Nature Genetics · doi:10.1038/ng.2387 · Cited by 266
Downregulation and/or Release of NKG2D Ligands as Immune Evasion Strategy of Human Neuroblastoma
Raffaghello, L., Prigione, I., Airoldi, I., Camoriano, M., Levreri, I., Gambini, C., Pende, D., Steinle, A., Ferrone, S., & Pistoia, V. (2004) · Neoplasia · doi:10.1593/neo.04316 · Cited by 264
Natural Killer Cell-Mediated Killing of Freshly Isolated Neuroblastoma Cells
Castriconi, R., Dondero, A., Corrias, M. V., Lanino, E., Pende, D., Moretta, L., Bottino, C., & Moretta, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2682 · Cited by 259
Kogner, P., Barbany, G., Dominici, C., Castello, M. A., Raschellà, G., & Persson, H. (1993) · PubMed · Cited by 247
DNA methylation inhibitors in cancer: Recent and future approaches
Gros, C., Fahy, J., Halby, L., Dufau, I., Erdmann, A., Gregoire, J.-M., Ausseil, F., Vispé, S., & Arimondo, P. B. (2012) · Biochimie · doi:10.1016/j.biochi.2012.07.025 · Cited by 245
On Trk—The TrkB Signal Transduction Pathway Is an Increasingly Important Target in Cancer Biology
Thiele, C. J., Li, Z., & McKee, A. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0651 · Cited by 238
A population-based study of the usefulness of screening for neuroblastoma
Woods, W. G., Tuchman, M., Robison, L. L., Bernstein, M., Leclerc, J.-M., Brisson, L. C., Brossard, J., Hill, G., Shuster, J., Luepker, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)06020-5 · Cited by 231
Resistance to chemotherapy mediated by TrkB in neuroblastomas.
Ho, R., Eggert, A., Hishiki, T., Minturn, J. E., Ikegaki, N., Foster, P., Camoratto, A. M., Evans, A. E., & Brodeur, G. M. (2002) · PubMed · Cited by 228
Self-citationEssential role of Gata transcription factors in sympathetic neuron development
Tsarovina, K., Pattyn, A., Stubbusch, J., Müller, F., van der Wees, J., Schneider, C., Brunet, J.-F., & Rohrer, H. (2004) · Development · doi:10.1242/dev.01370 · Cited by 226
Tsuzuki, T., Takahashi, M., Asai, N., Iwashita, T., Matsuyama, M., & Asai, J. (1995) · PubMed · Cited by 225
Inverse relationship between trk expression and N-myc amplification in human neuroblastomas.
Nakagawara, A., Arima, M., Azar, C. G., Scavarda, N. J., & Brodeur, G. M. (1992) · PubMed · Cited by 219
Self-citationNakamura, K., Martin, K. C., Jackson, J. K., Beppu, K., Woo, C.-W., & Thiele, C. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2789 · Cited by 218
Tacconelli, A., Farina, A. R., Cappabianca, L., DeSantis, G., Tessitore, A., Vetuschi, A., Sferra, R., Rucci, N., Argenti, B., Screpanti, I., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.011 · Cited by 208
George, R. E., Li, S., Medeiros-Nancarrow, C., Neuberg, D., Marcus, K., Shamberger, R. C., Pulsipher, M., Grupp, S. A., & Diller, L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6986 · Cited by 205
Jaboin, J. J., Kim, C. J., Kaplan, D. R., & Thiele, C. J. (2002) · PubMed · Cited by 201
Nuchtern, J. G., London, W. B., Barnewolt, C. E., Naranjo, A., McGrady, P. W., Geiger, J. D., Diller, L., Schmidt, M. L., Maris, J. M., Cohn, S. L., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31826cbbbd · Cited by 200
Fouladi, M., Park, J. R., Stewart, C. F., Gilbertson, R. J., Schaiquevich, P., Sun, J., Reid, J. M., Ames, M. M., Speights, R., Ingle, A. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9119 · Cited by 199
Matsumoto, K., Wada, R. K., Yamashiro, J. M., Kaplan, D., & Cj, T. (1995) · PubMed · Cited by 193
Schleiermacher, G., Mosseri, V, London, W. B., Maris, J. M., Brodeur, G. M., Attiyeh, E., Haber, M., Khan, J., Nakagawara, A., Speleman, F., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.375 · Cited by 192
Self-citationLack of High-Affinity Nerve Growth Factor Receptors in Aggressive Neuroblastomas
Suzuki, T., Bogenmann, E., Shimada, H., Stram, D., & Seeger, R. C. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.377 · Cited by 187
Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice
Heukamp, L. C., Thor, T., Schramm, A., De Preter, K., Kumps, C., De Wilde, B., Odersky, A., Peifer, M., Lindner, S., Spruessel, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003967 · Cited by 181
Expression of TrkA, TrkB and TrkC in human neuroblastomas
Brodeur, G. M., Nakagawara, A., Yamashiro, D. J., Ikegaki, N., Liu, X.-G., Azar, C. G., Lee, C. P., & Evans, A. E. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005729329526 · Cited by 172
Self-citationDependence receptors: a new paradigm in cell signaling and cancer therapy
Goldschneider, D., & Mehlen, P. (2010) · Oncogene · doi:10.1038/onc.2010.13 · Cited by 169
Garrison, F. H. (1926) · Europe PMC (PubMed Central) · Cited by 167
Nguyễn, L. B., Diskin, S. J., Capasso, M., Wang, K., Diamond, M. A., Glessner, J., Kim, C., Attiyeh, E. F., Mosse, Y. P., Cole, K., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002026 · Cited by 165
De Preter, K., Vandesompele, J., Heimann, P., Yigit, N., Beckman, S., Schramm, A., Eggert, A., Stallings, R. L., Benoit, Y., Renard, M., et al. (2006) · Genome Biology · doi:10.1186/gb-2006-7-9-r84 · Cited by 163
Prevalence and functional consequence of PHOX2B mutations in neuroblastoma
Raabe, E. H., Laudenslager, M., Winter, C. L., Wasserman, N. F., Cole, K. A., LaQuaglia, M. P., Maris, D. J., Mossé, Y. P., & Maris, J. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210659 · Cited by 162
Salcedo, R., Stauffer, J. K., Lincoln, E., Back, T. C., Hixon, J. A., Hahn, C., Shafer-Weaver, K., Malyguine, A., Kastelein, R., & Wigginton, J. M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7170 · Cited by 161
B- and T-cell markers in opsoclonus–myoclonus syndrome
Pranzatelli, M. R., Travelstead, A. L., Tate, E., Allison, T. J., Moticka, E. J., Franz, D. N., Nigro, M. A., Parke, J. T., Stumpf, D. A., & Verhulst, S. J. (2004) · Neurology · doi:10.1212/wnl.62.9.1526 · Cited by 156
Insights into neural crest development and evolution from genomic analysisPreprint
Simões-Costa, M., & Bronner-Fraser, M. E. (2013) · Genome Research · doi:10.1101/gr.157586.113 · Cited by 149
RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours
Astuti, D., Agathanggelou, A., Honorio, S., Dallol, A., Martinsson, T., Kogner, P., Cummins, C., Neumann, H. P. H., Voutilainen, R., Dahia, P. L. M., et al. (2001) · Oncogene · doi:10.1038/sj.onc.1204968 · Cited by 147
Why does stage 4s neuroblastoma regress spontaneously?
Pritchard, J. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92834-7 · Cited by 125
Fisher, J. P. H., & Tweddle, D. A. (2012) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2012.05.002 · Cited by 120
Methylation ofCASP8, DCR2, andHIN-1in Neuroblastoma Is Associated with Poor Outcome
Yang, Q., Kiernan, C. M., Tian, Y., Salwen, H. R., Chlenski, A., Brumback, B., London, W. B., & Cohn, S. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2846 · Cited by 113
Mossé, Y. P., Diskin, S. J., Wasserman, N. F., Rinaldi, K., Attiyeh, E. F., Cole, K. A., Jagannathan, J., Bhambhani, K., Winter, C. L., & Maris, J. M. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20477 · Cited by 110
Catecholamine Metabolism in Neuroblastoma 1 2
Labrosse, E. H., Comoy, E., Bohuon, C., Zucker, J., & Schweisguth, O. (1976) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/57.3.633 · Cited by 107
The natural history of neuroblastic cells in the fetal adrenal gland.
Turkel, S. B., & Itabashi, H. H. (1974) · PubMed · Cited by 107
Bosse, K. R., Diskin, S. J., Cole, K. A., Wood, A., Schnepp, R. W., Norris, G. T., Nguyễn, L. B., Jagannathan, J., LaQuaglia, M. P., Winter, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3703 · Cited by 106
Minturn, J. E., Evans, A. E., Villablanca, J. G., Yanik, G. A., Park, J. R., Shusterman, S., Groshen, S. G., Hellriegel, E. T., Bensen-Kennedy, D. M., Matthay, K. K., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1581-4 · Cited by 105
Self-citationRaffaghello, L., Prigione, I., Bocca, P., Morandi, F., Camoriano, M., Gambini, C., Wang, X., Ferrone, S., & Pistoia, V. (2005) · Oncogene · doi:10.1038/sj.onc.1208594 · Cited by 104
Salcedo, R., Hixon, J. A., Stauffer, J. K., Jalah, R., Brooks, A. D., Khan, T. M., Dai, R., Scheetz, L., Lincoln, E., Back, T. C., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0800471 · Cited by 99
EZH2 as a potential target in cancer therapy
McCabe, M. T., & Creasy, C. L. (2014) · Epigenomics · doi:10.2217/epi.14.23 · Cited by 96
Nakagawara, A. (1998) · PubMed · Cited by 89
Telomere length is a prognostic factor in neuroblastoma
Ohali, A., Avigad, S., Ash, S., Goshen, Y., Luria, D., Feinmesser, M., Zaizov, R., & Yaniv, I. (2006) · Cancer · doi:10.1002/cncr.22132 · Cited by 88
Congenital neuroblastoma, neuroblastoma in situ, and the normal fetal development of the adrenal
Ikeda, Y., Lister, J., Bouton, J. M., & Büyükpamukçu, M. (1981) · Journal of Pediatric Surgery · doi:10.1016/0022-3468(81)90019-1 · Cited by 86
Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts.
Evans, A. E., Kisselbach, K. D., Yamashiro, D. J., Ikegaki, N., Camoratto, A. M., Dionne, C. A., & Brodeur, G. M. (1999) · PubMed · Cited by 85
Self-citationAssociation of neurotrophin receptor expression and differentiation in human neuroblastoma.
Hoehner, J. C., Olsen, L., Sandstedt, B., Kaplan, D. R., & Påhlman, S. (1995) · Europe PMC (PubMed Central) · Cited by 84
Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13.
Maris, J. M., Weiss, M. J., Mossé, Y. P., Hii, G., Guo, C. H., White, P. S., Hogarty, M. D., Mirensky, T. L., Brodeur, G. M., Rebbeck, T. R., et al. (2002) · PubMed · Cited by 80
Self-citationYamamoto, K., Ohta, S., Ito, E., Hayashi, Y., Asami, T., Mabuchi, O., Higashigawa, M., & Tanimura, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1209 · Cited by 79
Bénard, J., Raguénez, G., Kauffmann, A., Valent, A., Ripoche, H., Joulin, V., Job, B., Danglot, G., Cantais, S., Robert, T., et al. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.07.002 · Cited by 73
Iyer, R., Evans, A. E., Qi, X.-X., Ho, R., Minturn, J. E., Zhao, H., Balamuth, N., Maris, J. M., & Brodeur, G. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1531 · Cited by 72
Self-citationRen, Y., Chan, H. M., Fan, J., Xie, Y., Chen, Y. X., Li, W. H., Jiang, G. P., Liu, Q., Meinhardt, A., & Tam, P. K. H. (2006) · Oncogene · doi:10.1038/sj.onc.1209395 · Cited by 71
Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma
Santo, E. E., Ebus, M. E., Köster, J., Schulte, J. H., Lakeman, A., Sluis, P. V., Vermeulen, J., Gisselsson, D., Øra, I., Lindner, S., et al. (2011) · Oncogene · doi:10.1038/onc.2011.344 · Cited by 68
Neuroblastoma epigenetics: From candidate gene approaches to genome-wide screenings
Decock, A., Ongenaert, M., Vandesompele, J., & Speleman, F. (2011) · Epigenetics · doi:10.4161/epi.6.8.16516 · Cited by 68
Role of neurotrophins and their receptors in human neuroblastomas: a primary culture study
Nakagawara, A., & Brodeur, G. M. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00280-3 · Cited by 67
Self-citationMdm2 Deficiency Suppresses MYCN-Driven Neuroblastoma Tumorigenesis In Vivo
Chen, Z., Lin, Y., Barbieri, E., Burlingame, S., Hicks, J. M., Ludwig, A. D., & Shohet, J. M. (2009) · Neoplasia · doi:10.1593/neo.09466 · Cited by 62
Expression of trkC receptor mRNA during development of the avian nervous system
Kahane, N., & Kalcheim, C. (1994) · Journal of Neurobiology · doi:10.1002/neu.480250509 · Cited by 62
Histone Chaperone CHAF1A Inhibits Differentiation and Promotes Aggressive Neuroblastoma
Barbieri, E., Preter, K. D., Capasso, M., Chen, Z., Hsu, D. M., Tonini, G. P., Lefever, S., Hicks, J. M., Versteeg, R., Pession, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1315 · Cited by 56
Transitioning from genotypes to epigenotypes: Why the time has come for medulloblastoma epigenomics
Batora, N. V., Sturm, D., Jones, D., Kool, M., Pfister, S. M., & Northcott, P. A. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.07.030 · Cited by 55
Krams, M., Hero, B., Berthold, F., Parwaresch, R. M., Harms, D., & Rudolph, P. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63896-5 · Cited by 54
Tacconelli, A., Farina, A. R., Cappabianca, L. A., Gulino, A., & Mackay, A. R. (2005) · Future Oncology · doi:10.2217/14796694.1.5.689 · Cited by 53
Telomerase Activity as a Prognostic Factor in Neuroblastomas
Streutker, C., Thorner, P. S., Fabricius, N., Weitzman, S. S., & Zieleńska, M. (2001) · Pediatric and Developmental Pathology · doi:10.1007/s100240010108 · Cited by 43
Stage 4S neuroblastoma: what makes it special?
Matthay, K. K. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2003 · Cited by 37
The effect of P75 on Trk receptors in neuroblastomas
Ho, R., Minturn, J. E., Simpson, A. M., Iyer, R., Light, J. E., Evans, A. E., & Brodeur, G. M. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.02.029 · Cited by 35
Self-citationde Braud, F., Pilla, L., Niger, M., Damian, S., Bardazza, B., Martinetti, A., Pelosi, G., Marrapese, G., Palmeri, L., Cerea, G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2502 · Cited by 32
Proteomics-based identification of spontaneous regression-associated proteins in neuroblastoma
Yu, F., Zhu, X.-D., Feng, C., Wang, T., Hong, Q., Liu, Z.-L., & Tang, S.-Q. (2011) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2011.06.024 · Cited by 28
Neurotrophin dependence mediated by p75NTR: contrast between rescue by BDNF and NGF
Rabizadeh, S., Rabizadeh, S., Ye, X., Wang, J. J., & Bredesen, D. E. (1999) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400614 · Cited by 28
Production of Macrophage Migration Inhibitory Factor by Human and Murine Neuroblastoma
Bin, Q., Johnson, B. D., Schauer, D. W., Casper, J. T., & Orentas, R. J. (2002) · Tumor Biology · doi:10.1159/000064028 · Cited by 22
Samy, M., Gattolliat, C., Pendino, F., Hillion, J., Nguyen, É., Bombard, S., Douc‐Rasy, S., Bénard, J., & Ségal-Bendirdjian, E. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0281 · Cited by 18
Cited by
Matthay, K. K., Maris, J. M., Schleiermacher, G., Nakagawara, A., Mackall, C. L., Diller, L., & Weiss, W. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.78 · Cited by 1,419
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
Auslander, N., Zhang, G., Lee, J. S., Frederick, D. T., Miao, B., Moll, T., Tian, T., Wei, Z., Madan, S., Sullivan, R. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0157-9 · Cited by 738
Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
Kim, C. G., Kim, K. H., Pyo, K.-H., Xin, C.-F., Hong, M. H., Ahn, B.-C., Kim, Y., Choi, S. J., Yoon, H. I., Lee, J. G., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz123 · Cited by 282
Neuroblastoma—A Neural Crest Derived Embryonal Malignancy
Johnsen, J. I., Dyberg, C., & Wickström, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00009 · Cited by 277
Dong, R., Yang, R., Zhan, Y., Lai, H.-D., Ye, C.-J., Yao, X.-Y., Luo, W.-Q., Cheng, X.-M., Miao, J.-J., Wang, J.-F., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.014 · Cited by 274
Metadata
- Authors
- Brodeur, G. M., & Bagatell, R.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2014-10-21
- Volume
- 11
- Issue
- 12
- Pages
- 704-713
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2036370250
- Cited by
- 284
- References
- 126
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.